Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.


Generic Name
Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins
DrugBank Accession Number

Adipose mesenchymal stem cells (AMSCs) are MSCs derived from adipose tissue, which is more accessible and less painful than stem cells extracted from most other sources. Autologous stem cells are those derived from a patient’s own cells while allogeneic stem cells are derived from that of a donor. Lipoaspiration, also known as liposuction, is a possible method for extraction. This is followed by purification and expansion of the cells in vitro.

These AMSCs are multipotent, with the capability of forming different tissues, some of which include bone, muscle, neural, and chondrocyte. This explains why AMSCs have been utilized in repairing craniofacial bone defects. They also have potential in treatment of scarred vocal folds.

Biologic Classification
Cell transplant therapies
Autologous cell transplant / Other cell transplant therapies
  • adMSC
  • AstroStem-V
  • CMTAd
  • HB-adMSCs
  • HCR040
  • PSC-04



Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more

Not Available

Mechanism of action

AMSCs have been shown to secrete several growth factors and hyaluronic acid (HA) which balance collagen, with hepatocyte growth factor (HGF) being a major part of those secreted. HGF secreted by AMSCs has been shown, in culture, to attenuate collagen production and fibroblast proliferation. AMSCs also have the ability to produce elastic fibers, something that typically does not appear in a scar environment.

In some studies, adipose mesenchymal stem cells have demonstrated anti-inflammatory and chondroprotective properties. Currently, the exact mechanism behind AMSCs is unknown. However, a possible mechanism consists of activation of the cells due to inflammation, with the activated cells then modulating inflammation and cartilage remodeling by prostaglandin E2. The effects for AMSCs seem to also possibly be dose-dependent.


Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Not Available
Route of elimination

Not Available


Not Available


Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample

Not Available

Not Available
Pharmacogenomic Effects/ADRs
Not Available


Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available


Drug Categories
Not Available
Not classified
Affected organisms
Not Available

Chemical Identifiers

CAS number
Not Available


General References
  1. Mazini L, Rochette L, Amine M, Malka G: Regenerative Capacity of Adipose Derived Stem Cells (ADSCs), Comparison with Mesenchymal Stem Cells (MSCs). Int J Mol Sci. 2019 May 22;20(10). pii: ijms20102523. doi: 10.3390/ijms20102523. [Article]
  2. Zakrzewski W, Dobrzynski M, Szymonowicz M, Rybak Z: Stem cells: past, present, and future. Stem Cell Res Ther. 2019 Feb 26;10(1):68. doi: 10.1186/s13287-019-1165-5. [Article]
Not Available

Clinical Trials

Clinical Trials
2Active Not RecruitingTreatmentMultiple Sclerosis1
2CompletedPreventionCoronavirus Disease 2019 (COVID‑19)2
2CompletedTreatmentCoronavirus Disease 2019 (COVID‑19) / Post COVID-19 Syndrome1
2CompletedTreatmentParkinson's Disease (PD)1
2RecruitingTreatmentParkinson's Disease (PD)1


Not Available
Not Available
Dosage Forms
Not Available
Not Available
Not Available


Not Available
Experimental Properties
Not Available

Drug created at August 11, 2020 19:09 / Updated at June 30, 2023 06:40